Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2015-09-28 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a short filing (2331 characters) announcing a press release about a clinical study dosing event. It includes no financial statements or detailed financial data, only a reference to a press release as an exhibit. The document is not an annual or quarterly report, nor an earnings release, nor a management discussion. It is a regulatory announcement of a material event. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-09-28 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 31, 2015, by Lipocine Inc. The key content is an update to the company's corporate presentation used for investor meetings, attached as Exhibit 99.1. The document does not contain financial statements or detailed financial analysis but rather an updated presentation. The length is 2206 characters, which is relatively short and consistent with an announcement or update rather than a full report. According to the definitions, an updated corporate presentation for investors fits best under 'Investor Presentation (IP)'.
2015-08-31 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it reports the submission of a new drug application to the FDA and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is relatively short (2465 characters) and primarily serves as an announcement of a significant corporate event rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-08-31 English
FORM 8-K
Investor Presentation Classification · 90% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2015, by Lipocine Inc. It announces the company's participation in the 35th Annual Canaccord Genuity Growth Conference and mentions that presentation materials are attached as exhibits. The document itself is a current report disclosing Regulation FD information and investor presentation materials. The length is 2359 characters, which is relatively short and primarily serves as an announcement rather than the full presentation or report. According to the 'Menu vs Meal' rule, this is an announcement of presentations, not the presentations themselves. Therefore, the appropriate classification is Investor Presentation (IP) because the main content relates to investor presentations and materials for a conference, but since the document is short and only announces the presentations, it fits best as an Investor Presentation announcement. However, since the document is a Form 8-K announcing presentations and includes the presentations as exhibits, the best fit is Investor Presentation (IP).
2015-08-12 English
FORM 8-K
Earnings Release Classification · 90% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company, Lipocine Inc., issued a press release reporting financial and operational results for the second quarter ended June 30, 2015. The actual financial results are contained in the press release filed as Exhibit 99.1, not in this document itself. The Form 8-K serves as an announcement of the earnings release rather than the earnings release itself. The document length is short (2356 characters), and it references the press release rather than containing substantive financial data. Therefore, this document is best classified as an Earnings Release announcement (ER) or possibly Regulatory Filings (RNS). However, since it specifically states it is reporting financial results via a press release, the best fit is Earnings Release (ER).
2015-08-11 English
10-Q
Interim / Quarterly Report Q2 2015
2015-08-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.